It is worth pointing out that miR-34a mimic, MRX34, is the first miRNA mimic currently evaluated in a multicenter phase I study in patients with hematological malignancies including CLL (ClinicalTrials.gov Identifier NCT01829971) [59]. The gene discussed is IL1RAPL1; the disease is hematologic disorder.